- B-cell
chronic lymphocytic leukemia. Cladribine, sold
under the
brand name
Mavenclad, is used for the
treatment of
adults with
highly active forms of relapsing-remitting...
-
Switzerland to Darmstadt.
Drugs they
market include Erbitux, UFT, Rebif,
Mavenclad, Novantrone, Gonal, Ovidrel/Ovitrelle, Zorbtive, Luveris, Saizen, Serostim...
- [better source needed] Oral 0.18-0.24
Kesimpta Ofatumumab Subcutaneous 70% 0.09-0.14
Mavenclad Cladribine Oral 70% 0.1-0.14
Lemtrada Alemtuzumab Intravenous 70% 0.08...
-
development of
cotton wool spots. Cladribine, also
known by its
brand name
Mavenclad, is a
purine antimetabolite and
antineoplastic drug used to
reduce relapse...
-
Administration (FDA). 3 May 2019.
Retrieved 26
March 2020. "Drug
Approval Package:
Mavenclad (cladribine)". U.S. Food and Drug
Administration (FDA). 22 July 2019....
- progressive) in
Europe in 2017 and by FDA in
April 2019 with the name
Mavenclad.
Active SPMS (aSPMS,
formerly progressive-relapsing): In the US, the approval...
-
example the Food and Drug
Administration approved cladribine tablets (
Mavenclad) to
treat relapsing forms of
multiple sclerosis (MS) in adults, to include...
